Results 241 to 250 of about 1,594,150 (301)

GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

Chronic Diseases and Translational Medicine, EarlyView.
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves, Masatoki Teranishi, Rajendranandini Majumdar, Fazal Khan, Mohan Dodeja, Ana Claudia Teixeira de Castro Gonçalves Ortega, Marco Acerboni, Arosh S. Perera Molligoda Arachchige, Frank James   +8 more
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

Hip fracture and type 2 diabetes mellitus

Osteoporosis and Sarcopenia
Ji-Young Seo
doaj   +1 more source

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh, Ofek Levi, Nili Stein, Amir Yahav, Naomi Gronich   +4 more
wiley   +1 more source

Global, regional, and national burden of chronic kidney disease due to diabetes mellitus type 2 from 1990 to 2021, with projections to 2036: a systematic analysis for the Global Burden of Disease Study 2021. [PDF]

Front Med (Lausanne)
Hu R, Zhao Z, Xie L, Ma Z, Wu W, Li S.
europepmc   +1 more source

Implementation of OMOP and ConcePTION Common Data Models in CPRD GOLD: Risk of Bleeding and Cardiovascular Outcomes From Anticoagulant Use

Clinical Pharmacology &Therapeutics, EarlyView.
The impact of the choice of common data model (CDM) approach on the study results in a real‐world evidence (RWE) study is unknown. We aimed to determine potential differences in the results of an RWE study when data were mapped to two different CDMs, ConcePTION and OMOP. With the same instance of CPRD GOLD, data were mapped to both CDMs. Using the same
Nicholas B. Hunt, Patrick Souverein, Marloes Bazelier, Nicola Barclay, Antonella Delmestri, Miriam Sturkenboom, Daniel Prieto‐Alhambra, Helga Gardarsdottir, Olaf Klungel   +8 more
wiley   +1 more source

Effectiveness of Integrated Care for Diabetes Mellitus Type 2, Cardiovascular and Chronic Respiratory Diseases: A Systematic Review and Meta-Analysis. [PDF]

Int J Integr Care
Valentijn PP, Tymchenko L, Gruisen W, Bruls B, Abdalla Pereira F, Arends RY.   +5 more
europepmc   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Validation of the Internal Coherence Scale (ICS) in Healthy Geriatric Individuals and Patients Suffering from Diabetes Mellitus Type 2 and Cancer. [PDF]

Geriatrics (Basel)
Mehl A, Klaus AK, Reif M, Rodrigues Recchia D, Zerm R, Ostermann T, Brinkhaus B, Kröz M.   +7 more
europepmc   +1 more source